Buchumschlag

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Carl Eriksson, Jiangwei Sun, Matti Bryder, Gabriella Bröms, Åsa H. Everhov, Anders Forss, Tomas Jernberg, Jonas F. Ludvigsson, Ola Olén
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
von: Adam S. Faye, et al.
Veröffentlicht: (2025)

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
von: Mehdi Osooli, et al.
Veröffentlicht: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
von: Fahim Ebrahimi, et al.
Veröffentlicht: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Antibiotic Use and Risk of Microscopic Colitis in Older Adults: A Nationwide Self‐Controlled Case Series Study
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Letter: Irritable bowel syndrome and antibiotics
von: George F. Longstreth
Veröffentlicht: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
von: Sérgio Bronze, et al.
Veröffentlicht: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
von: Konstantinos Arvanitakis, et al.
Veröffentlicht: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
von: Nurulamin M. Noor, et al.
Veröffentlicht: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
von: Tsz Hong Yiu, et al.
Veröffentlicht: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
von: Peter R. Gibson, et al.
Veröffentlicht: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
von: Maryam Kharal, et al.
Veröffentlicht: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts
von: Karl Mårild, et al.
Veröffentlicht: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
von: Amanda Ricciuto, et al.
Veröffentlicht: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
von: Thanaboon Chaemsupaphan, et al.
Veröffentlicht: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
von: Léa Sequier, et al.
Veröffentlicht: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
von: R. M. Mathias, et al.
Veröffentlicht: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
von: Christy Riggott, et al.
Veröffentlicht: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
von: Iris Barth, et al.
Veröffentlicht: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
von: Ayesha Shah, et al.
Veröffentlicht: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
von: Aakash Desai, et al.
Veröffentlicht: (2024)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
von: Fangyuan Jiang, et al.
Veröffentlicht: (2024)

Women's Health Disorders in a Coeliac Disease Population After Diagnosis—A Nationwide Cohort Analysis
von: Rama Nanah, et al.
Veröffentlicht: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
von: Seogsong Jeong, et al.
Veröffentlicht: (2026)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
von: Kyuwon Kim, et al.
Veröffentlicht: (2024)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
von: Saad Khan, et al.
Veröffentlicht: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
von: Rie Louise Møller Nordestgaard, et al.
Veröffentlicht: (2024)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
von: Samantha Baillie, et al.
Veröffentlicht: (2025)

Editorial: Disordered eating and irritable bowel syndrome—Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?
von: Andrea Shin
Veröffentlicht: (2024)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
von: Laurent Lam, et al.
Veröffentlicht: (2024)